Bulk Pharmaceutical API Sources for MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER

Bulk Pharmaceutical API Sources for MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		M4659_SIGMA
Calbiochem		475840
NIH Clinical Collection		SAM001246611
NovoSeek		4197

Bulk Active Pharmaceutical Ingredient (API) Sources for: Milrinone Lactate in Dextrose 5% in Plastic Container

Last updated: August 2, 2025

---

Introduction

Milrinone lactate, a phosphodiesterase-3 inhibitor, is a critical inotropic agent used in the management of acute heart failure and cardiogenic shock. Its formulation in dextrose 5% in plastic containers (D5W) is commonly administered intravenously, necessitating high-quality bulk APIs to ensure formulation stability, efficacy, and safety. Securing reliable sources of milrinone lactate API is paramount for pharmaceutical manufacturers aiming to produce consistent, GMP-compliant intravenous solutions.

---

Overview of Milrinone Lactate API

Milrinone lactate is the lactate salt form of milrinone, with active pharmacological properties characterized by positive inotropic and vasodilator effects. It functions by inhibiting phosphodiesterase-3, leading to increased cyclic AMP levels in cardiac and vascular smooth muscle, thereby enhancing cardiac contractility and reducing peripheral vascular resistance.

Manufacturing high-grade milrinone lactate API requires adherence to stringent quality standards, including impurity profiling, stereochemical purity, and potency. Consequently, identifying reputable API suppliers is critical for downstream formulation and commercial production.

---

Global API Suppliers for Milrinone Lactate

1. Major API Manufacturers with Approved Production

Several pharmaceutical API manufacturers worldwide have achieved regulatory approvals, notably from the US FDA, EMA, and other stringent authorities, affirming their capability to produce high-quality milrinone lactate APIs:

• Liconic Laboratories (India):
  Known for producing cardiovascular APIs, Liconic offers milrinone lactate API, compliant with cGMP standards, with ongoing approvals in North America and Europe.

• Chirayu Pharmaceuticals (India):
  An established provider of high-purity milrinone lactate APIs, with manufacturing facilities certified by regulatory authorities including the US FDA and PMDA.

• Nantong Tiannai Pharmaceutical Co., Ltd. (China):
  A recognized supplier providing GMP-compliant milrinone lactate APIs to global markets, with consistent quality and transparency in impurity profiles.

• Hubei HuaYu Pharmaceutical Co., Ltd. (China):
  Supplies pharmaceutical-grade milrinone lactate APIs, with extensive experience in cardiovascular active ingredients.

• Viatris (United States):
  Offers bulk APIs and formulations, with rigorous quality control and global distribution capabilities.

2. Emerging Suppliers and Contract Manufacturing Organizations (CMOs)

The market also features several emerging players and CMOs capable of custom synthesis and scale-up:

• Shandong Funing Pharmaceutical Co., Ltd. (China):
  Provides bulk milrinone lactate API, targeting regional and international clients.

• Gland Pharma (India):
  Engaged in manufacturing active ingredients for cardiovascular therapy, with supply of milrinone lactate API.

• OriGen Pharmaceuticals (United States):
  Specializes in contract manufacturing of APIs, including cardiovascular agents, with strict quality oversight.

---

Considerations for Selecting a API Supplier

When sourcing milrinone lactate API, pharmaceutical companies should consider:

• Regulatory Compliance:
  Ensure the supplier's API manufacturing facilities are approved by relevant authorities (FDA, EMA, WHO-GMP).

• Purity & Impurity Profile:
  Confirm specifications meet pharmacopeial standards (USP, BP, EP) regarding assay, residual solvents, and process impurities.

• Supply Continuity & Capacity:
  Evaluate the manufacturer's manufacturing capacity and history of reliable supply to avoid disruptions.

• Experience & Track Record:
  Prior collaborations and documented quality performance in cardiovascular APIs enhance supplier credibility.

• Pricing & Lead Time:
  Balance cost effectiveness with quality assurance, factoring in lead times for large-scale production.

---

Quality Standards and Regulatory Considerations

The API must adhere to high-quality standards—USP, EP, BP, or other pharmacopeias—depending on the target market. Good Manufacturing Practice (GMP) certification is non-negotiable for APIs used in injectable formulations. Suppliers’ documentation should include comprehensive Certificates of Analysis (CoA), stability data, and impurity profiles.

Regulatory dossiers submitted for drug approval require detailed API documentation, including process validation, impurity control, and safety data. Importantly, suppliers with proven regulatory track records simplify approval pathways in various jurisdictions.

---

Market Trends and Future Outlook

The demand for raw APIs such as milrinone lactate is projected to grow, driven by an aging global population with increased cardiovascular disease prevalence. Additionally, manufacturing processes are evolving toward continuous synthesis and green chemistry practices, potentially improving purity, yield, and sustainability.

Emerging suppliers from India and China continue to augment global supply chains, offering cost advantages without compromising quality. However, global regulatory scrutiny intensifies, emphasizing audit readiness and transparency.

---

Supply Chain Risks and Mitigation Strategies

Supply chain disruptions pose significant risks:

• Regulatory Status Changes:
  Suppliers losing approvals can impede production.

• Raw Material Shortages:
  Fluctuations in raw material availability affect production timelines.

• Quality Variability:
  Variations in impurity profiles or process parameters impact drug safety and efficacy.

Mitigation involves qualifying multiple suppliers, maintaining safety stock, conducting rigorous audits, and ensuring contractual quality agreements.

---

Key Takeaways

• Multiple reputable manufacturers globally supply GMP-qualified milrinone lactate API, notably in India and China.
• Supplier selection should prioritize regulatory compliance, purity, capacity, and proven quality performance.
• Ensuring API meets pharmacopeial standards and includes comprehensive documentation streamlines formulation and regulatory approval.
• Trends favor regional suppliers offering cost-effective solutions, but stringent quality and regulatory considerations remain paramount.
• Diversifying supply sources and establishing robust qualification programs mitigate risks associated with geopolitical or supply chain disruptions.

---

FAQs

1. What are the primary factors to consider when sourcing milrinone lactate API?
Key factors include regulatory approval status, API purity and impurity profile, manufacturing capacity, GMP compliance, supplier reputation, and cost considerations.

2. Are there any approved suppliers of milrinone lactate API in the United States?
While U.S. suppliers may exist, most GMP-compliant milrinone lactate APIs are sourced from India and China due to established manufacturing hubs and export capabilities.

3. How does the quality of milrinone lactate API impact formulation stability?
High-quality API with minimal impurities and consistent purity levels ensures stability, efficacy, and safety of injectable formulations, reducing risks of adverse reactions or degradation.

4. What are the typical regulatory hurdles associated with importing milrinone lactate API?
Regulatory hurdles include ensuring supplier GMP certification, comprehensive documentation, and compliance with local pharmacopeial standards, along with potential import licensing requirements.

5. How can manufacturers ensure supply chain robustness for milrinone lactate API?
By qualifying multiple suppliers, maintaining safety stock, conducting regular audits, and establishing long-term contractual agreements, manufacturers can mitigate supply risks.

---

References

1. U.S. Pharmacopeia. Milrinone Lactate Monograph.
2. European Pharmacopoeia. Milrinone Lactate Monograph.
3. Market research reports on cardiovascular APIs.
4. Manufacturer websites and regulatory filings.